We studied the phannacokinetics of erythromycin estolate and ethylsuccinate suspensions in infants under 4 months of age who were being treated for chlamydial infections or pertussis. We conducted our studies after the initial dose of 10 mg/kg and subsequently during steady-state treatment. The estolate preparation resulted in higher peak concentrations in sera, and its absorption and elimination half-lives were longer. Peak concentrations occurred 3 h after a dose with the estolate preparation and 1 h after a dose with the ethylsuccinate preparation. The area under the curve for the estolate preparation was about three times greater than that for the ethylsuccinate preparation. Based on these findings, we recommend that erythromycin estolate suspensions be given to young infants at 8-or 12-h intervals (30 mg/kg per day in three divided doses or 20 mg/kg per day in two divided doses) and that erythromycin ethylsuccinate is best given at 6-h intervals (40 mg/kg per day in four divided doses).
We studied the phannacokinetics of erythromycin estolate and ethylsuccinate suspensions in infants under 4 months of age who were being treated for chlamydial infections or pertussis. We conducted our studies after the initial dose of 10 mg/kg and subsequently during steady-state treatment. The estolate preparation resulted in higher peak concentrations in sera, and its absorption and elimination half-lives were longer. Peak concentrations occurred 3 h after a dose with the estolate preparation and 1 h after a dose with the ethylsuccinate preparation. The area under the curve for the estolate preparation was about three times greater than that for the ethylsuccinate preparation. Based on these findings, we recommend that erythromycin estolate suspensions be given to young infants at 8-or 12-h intervals (30 mg/kg per day in three divided doses or 20 mg/kg per day in two divided doses) and that erythromycin ethylsuccinate is best given at 6-h intervals (40 mg/kg per day in four divided doses).
Erythromycin is recommended and used for treatment of chlamydial infections and pertussis in young infants. To our knowledge, the only previously reported pharmacokinetic data concerning this age group were from a study in which the estolate salt of erythromycin was given to preterm infants (1). Our study involved a pharmacokinetic evaluation in infants under 4 months of age of the two forms of erythromycin available in suspension, namely, the ethylsuccinate salt and the estolate salt.
MATERLALS AND METHODS
The parents of patients under 4 
RESULTS
Between February 1980 and August 1980, we studied 30 patients. Two patients were excluded from our analysis because one had received an unknown drug which interfered with the erythromycin assay and the other was given penicillin during the study period. Thus, 28 patients were analyzed for the pharnacokinetics of erythromycin. Each study group contained six patients, except for the estolate preparation steady-state study with the drug given every 6 or 12 h, in which each group contained five patients. The mean body weight in the study groups varied from 3.5 to 4.6 kg, and the mean age varied from 29 to 49 days; these differences were not significant.
Initial dose study. In the initial dose study ( Fig. 1 Steady-state study. In the steady-state study ( Fig. 2 and Table 1 ), the trend to differences found after the initial dose persisted and were magnified when the drugs were given every 6 h. There were significant differences between the times until peak serum concentrations were attained (P < 0.001), the absorption half-lives (P < 0.004), the elimination half-lives (P < 0.054), and the AUC (P < 0.046). In all cases, the values in patients taking the estolate preparation were greater. The greater peak serum concentration found in infants taking the estolate preparation was not significant (P < 0.142).
When the estolate preparation was given every 12 h, the pharmacokinetic values obtained were similar to the values observed in infants taking the drug every 6 h ( Fig. 2 and Table 1 ). The peak serum concentrations of erythromycin achieved with the two suspensions used are two to three times greater than the highest minimal inhibitory concentrations (MICs) reported for Chlamydia trachomatis (0.5 ,g/ml) (6) and six to eight times greater than MICs reported for Bordetella pertussis (0.2 ,tg/ml) (3).
Trough serum levels 8 h after the estolate treatment were still greater than the MICs for C. trachomatis and B. pertussis. After erythromycin ethylsuccinate administration, the trough serum levels of erythromycin were lower than the MICs for the majority of C. trachomatis strains and only slightly higher than the MICs for B. pertussis.
The amount of time that erythromycin serum concentrations were maintained over 0.5 ,tg/ml was estimated by using the computer to be 10.5 h with the estolate preparation and 4.8 h with the ethylsuccinate suspension. Therefore, if maintenance of suprainhibitory antibiotic concentrations in serum is desirable for treating chlamydial infections, the estolate preparation could be given at 8-or 12-h intervals, and the ethylsuccinate preparation could be given at 6-h intervals. However, serum concentrations may be less important than antibiotic contents in tissues and other body fluids. It is characteristic of erythromycin that tissue and other body fluid levels are greater than levels in the serum (5) . This was supported by the observation in our study that erythromycin concentrations in tears were greater than the highest serum concentration in the majority of patients. Therefore, the relevance of serum concentrations to clinical efficacy can be misleading, and concentrations in the body fluids or tissues of the patient being treated may be a more reliable criterion.
There have been only two previous studies of erythromycin pharmacokinetics in infants; one was with preterm neonates (1) , and one was with older infants (7) . From the data in these reports we calculated pharmacokinetic values by using the same methods that we applied to our data ( Table 2) . The data are similar in the studies, with the notable exceptions of the far greater peak serum concentrations and AUC in the older infants taking erythromycin estolate. The most obvious explanation for this is the smaller volume of distribution in the older infants, but other factors may be operative. With both forms of erythromycin, the absorption half-lives were shorter in the older infants, but elimination halflives were similar. In our study erythromycin concentrations were determined by a microbioassay which measured total erythromycin content. A large portion of the erythromycin in the sera of patients receiving the estolate preparation was in the form of erythromycin propionate, which is biologically inactive (2, 9) . During the bioassay procedure, the propionate salt is hydrolyzed to yield erythromycin base. It is not known whether similar hydrolysis occurs in body fluids or tissues, and the clinical significance of this hydrolysis is disputed. From a practical standpoint, we have shown that infants with chlamydial conjunctivitis treated with 10 mg of the estolate preparation per kg every 12 h responded as well as those given the same dosage of the ethylsuccinate preparation every 6 h (P. Patamasucon, P. J. Rettig, K. Faust, and J. D. Nelson, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 20th, New Orleans, La., abstr. no. 528, 1980).
Based upon these pharmacokinetic studies, we recommend that infants under 4 months of age being treated for chlamydial infections or pertussis be given the estolate suspension at 8-or 12-h intervals (30 mg/kg per day in three divided doses or 20 mg/kg per day in two divided doses) or the ethylsuccinate suspension at 6-h intervals (40 mg/kg per day in four divided doses).
